Market Cap (In USD)
72.52 Million
Revenue (In USD)
2.3 Million
Net Income (In USD)
-26.77 Million
Avg. Volume
13.31 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.9-15.8
- PE
- -
- EPS
- -
- Beta Value
- 2.08
- ISIN
- US48669G1058
- CUSIP
- 48669G105
- CIK
- 1075880
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John Edwin Friend II, M.D.
- Employee Count
- -
- Website
- https://www.kaziatherapeutics.com
- Ipo Date
- 1999-01-06
- Details
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
More Stocks
-
RTGRTG Mining Inc.
RTG
-
WTHVFWesthaven Gold Corp.
WTHVF
-
CBDX
-
ADTLFAdriatic Metals PLC
ADTLF
-
CROSCrosswood SA
CROS
-
NDLSNoodles & Company
NDLS
-
RWB
-
IBTNInsCorp, Inc.
IBTN